How big is Ionis Pharmaceuticals, Inc.?

As of Jun 18, Ionis Pharmaceuticals, Inc. has a market capitalization of $5.75 billion, with net sales of $717.67 million and a net profit of -$457.69 million over the latest four quarters.

As of Jun 18, Ionis Pharmaceuticals, Inc. has a market capitalization of 5,753.60 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 717.67 million, while the sum of net profit for the same period is -457.69 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 588.35 million and total assets amounting to 3,003.68 million.

What does Ionis Pharmaceuticals, Inc. do?

Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics and reported net sales of $132 million with a net loss of $147 million as of March 2025. The company has a market cap of approximately $5.75 billion and does not pay dividends.

Overview: <BR>Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics within the Pharmaceuticals & Biotechnology industry, classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 132 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -147 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 5,753.60 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.73 <BR>Return on Equity: -94.65% <BR>Price to Book: 12.09<BR><BR>Contact Details: <BR>Address: 2855 Gazelle Ct, CARLSBAD CA: 92010-6670 <BR>Tel: ['1 760 9319200', '1 760 6032331'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.ionispharma.com/

Should I buy, sell or hold Ionis Pharmaceuticals, Inc.?

Who are in the management team of Ionis Pharmaceuticals, Inc.?

As of March 2022, the management team of Ionis Pharmaceuticals, Inc. includes Dr. Stanley Crooke (Executive Chairman), Dr. Brett Monia (CEO), and several directors, including Ms. Joan Herman, Ms. B. Lynne Parshall, Dr. Spencer Berthelsen, Mr. Breaux Castleman, and Dr. Michael Hayden.

As of March 2022, the management team of Ionis Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Stanley Crooke, who serves as the Executive Chairman of the Board of Directors.<BR>- Dr. Brett Monia, who is the Chief Executive Officer and a Director.<BR>- Ms. Joan Herman, who is a Director.<BR>- Ms. B. Lynne Parshall, who is also a Director.<BR>- Dr. Spencer Berthelsen, who serves as an Independent Director.<BR>- Mr. Breaux Castleman, who is an Independent Director.<BR>- Dr. Michael Hayden, who is another Independent Director.<BR><BR>In summary, the management team consists of key executives and directors, including Dr. Crooke and Dr. Monia in prominent leadership roles.

Is Ionis Pharmaceuticals, Inc. overvalued or undervalued?

As of February 22, 2023, Ionis Pharmaceuticals is considered risky and overvalued due to a high Price to Book Value of 11.81, a negative ROE of -94.65%, and a low EV to EBITDA ratio of -11.71, despite a strong recent stock return of 76.60%.

As of 22 February 2023, the valuation grade for Ionis Pharmaceuticals, Inc. has moved from fair to risky, indicating a more cautious outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 11.81 and a troubling ROE of -94.65%. Additionally, the EV to Sales ratio stands at 7.34, suggesting that the market may be pricing in expectations that are not supported by the company's current performance.<BR><BR>In comparison to its peers, Ionis Pharmaceuticals has a significantly lower EV to EBITDA ratio of -11.71, while Neurocrine Biosciences, Inc. is considered expensive with an EV to EBITDA of 25.2794. This stark contrast highlights the challenges Ionis faces in justifying its valuation. Despite a strong year-to-date stock return of 76.60% compared to the S&P 500's 12.22%, the long-term performance shows a decline, with a 3-year return of 33.26% versus the S&P's 70.41%. This suggests that while recent performance may seem promising, the overall valuation remains concerning.

Is Ionis Pharmaceuticals, Inc. technically bullish or bearish?

As of July 7, 2025, Ionis Pharmaceuticals shows a bullish technical trend supported by positive MACD and moving averages, but caution is advised due to bearish RSI readings despite strong recent performance compared to the S&P 500.

As of 7 July 2025, the technical trend for Ionis Pharmaceuticals, Inc. has changed from mildly bearish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. However, the RSI readings are bearish on both weekly and monthly time frames, indicating potential overbought conditions. The Bollinger Bands suggest a mildly bullish stance on the weekly and bullish on the monthly. Daily moving averages are bullish, while the KST is bullish weekly and mildly bullish monthly. Dow Theory shows no trend weekly but is mildly bullish monthly, and the OBV is bullish monthly.<BR><BR>In terms of performance, Ionis Pharmaceuticals has significantly outperformed the S&P 500 over the past month (42.16% vs. 2.33%) and year-to-date (76.60% vs. 12.22%), but it has lagged behind the benchmark over the longer three, five, and ten-year periods. Overall, the current technical stance is bullish, but caution is warranted due to the bearish RSI readings.